Molecular docking studies of flavonoids from Andrographis paniculata as potential acetylcholinesterase, butyrylcholinesterase and monoamine oxidase inhibitors towards the treatment of neurodegenerative diseases

Ahmed Adebayo Ishola, Babatunji Emmanuel Oyinloye, Basiru Olaitan Ajiboye, Abidemi Paul Kappo

Research output: Contribution to journalArticlepeer-review

18 Citations (Scopus)

Abstract

Neurodegenerative diseases have been characterized by loss of neuron structures as well as their functions. This study was designed to assess molecular docking of flavonoids from Andrographis paniculata as potential acetylcholinesterase, butyrylcholinesterase, and monoamine oxidase inhibitors in the treatment of neurodegenerative diseases. Eight identified possible inhibitors of acetylcholinesterase, butyrylcholinesterase, and monoamine oxidase from Andrographis paniculata were retrieved from the PubChem database. The molecular docking, ADMET, and Lipinski’s rule of five were examined using different bioinformatic tools. It was shown that only rutin has the highest binding affinity (-12.6 kcal/mol) than the standard used. ADMET results demonstrated that all the eight compounds are druggable candidates except rutin. Also, only tangeritin has a blood-brain barrier (BBB) permeation potential. Hence, it can be deduced that all flavonoid compounds from Andrographis paniculata are orally druggable, which can make them useful in the treatment of neurodegenerative diseases better than donepezil.

Original languageEnglish
Pages (from-to)9871-9879
Number of pages9
JournalBiointerface Research in Applied Chemistry
Volume11
Issue number3
DOIs
Publication statusPublished - 15 Jun 2021

Keywords

  • Andrographis paniculata
  • Flavonoid
  • Lipinski’s rule of five
  • Molecular docking
  • Neurodegenerative diseases

ASJC Scopus subject areas

  • Biotechnology
  • Biochemistry
  • Molecular Medicine
  • Molecular Biology

Fingerprint

Dive into the research topics of 'Molecular docking studies of flavonoids from Andrographis paniculata as potential acetylcholinesterase, butyrylcholinesterase and monoamine oxidase inhibitors towards the treatment of neurodegenerative diseases'. Together they form a unique fingerprint.

Cite this